New cancer drug SIM0610 enters first human tests
NCT ID NCT07348211
First seen Jan 17, 2026 · Last updated Jun 22, 2026 · Updated 24 times
Summary
This early-phase trial is testing an experimental drug called SIM0610 in 260 adults with advanced solid tumors, including lung, colorectal, head and neck, and liver cancers. The main goals are to check the drug's safety, find the right dose, and see if it shrinks tumors. Participants receive the drug through an IV infusion.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOURS are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Chongqing Cancer Hospital
NOT_YET_RECRUITINGChongqing, Chongqing Municipality, 400000, China
Contact
-
Harbin Medical University Cancer Hospital
NOT_YET_RECRUITINGHarbin, Heilongjiang, 150000, China
Contact
-
Shanghai East Hospital
NOT_YET_RECRUITINGShanghai, Shanghai Municipality, 200000, China
Contact
-
Shanghai Pulmonary Hospital
NOT_YET_RECRUITINGShanghai, Shanghai Municipality, 200000, China
Contact
-
The Affiliated Cancer Hospital of Shandong First Medical University& Shan Dong Cancer Hospital
RECRUITINGJinan, Shandong, 250117, China
Contact
-
Zhongshan Hospital, Fudan University
NOT_YET_RECRUITINGShanghai, Shanghai Municipality, 200000, China
Contact
-
the First Hospital of China Medical University
NOT_YET_RECRUITINGShenyang, Liaoning, 110000, China
Contact
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
SIM0610 (an experimental drug given by intravenous infusion)
What this could lead to
If successful, this could point toward a new treatment option for several advanced solid tumors.
What could go wrong
This is a very early Phase 1 trial, so the drug may not be safe or effective. It is the first time SIM0610 is tested in humans, and many early-stage drugs never advance.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.